Effect of Pregnancy on Unbound Raltegravir Concentrations in the ANRS 160 RalFe Trial-Reference-Cited by-同舟云学术

Effect of Pregnancy on Unbound Raltegravir Concentrations in the ANRS 160 RalFe Trial

Published:2020-09-21 Issue:10 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Zheng Yi¹²,Hirt Déborah¹²³^ORCID,Delmas Sandrine⁴,Lui Gabrielle¹²,Benaboud Sihem¹²,Lechedanec Jerome⁴,Tréluyer Jean-Marc¹²⁵,Chenevier-Gobeaux Camille⁶,Arezes Elisa⁴,Gelley Ambre⁷,Amri Imane⁷,Urien Saïk²⁵⁸,Bouazza Naïm²⁵⁸,Foissac Frantz²⁵⁸,Warszawski Josiane³⁴,Ghosn Jade⁹¹⁰

Affiliation:

1. Service de Pharmacologie Clinique, AP-HP, Hôpital Cochin, Paris, France

2. EA7323, Université de Paris, Paris, France

3. Inserm 1018 CESP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France

4. Service d’Epidémiologie et Santé Publique, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France

5. Unité de Recherche Clinique Paris Descartes Necker Cochin, AP-HP, Paris, France

6. Service de Diagnostic Biologique Automatisé, AP-HP, Hôpital Cochin, Paris, France

7. ANRS, France Recherche Nord&Sud Sida-hiv Hépatites, Paris, France

8. CIC-1419 Inserm, Cochin-Necker, Paris, France

9. Service des Maladies Infectieuses et Tropicales, AP-HP, Hôpitaux Universitaires Paris Nord Val de Seine, site Bichat-Claude Bernard, Paris, France

10. INSERM UMR 1137 IAME, Université Paris Diderot, Faculté de Médecine site Bichat, Paris, France

Abstract

A population pharmacokinetic model was developed to explore the pharmacokinetics modification of unbound raltegravir during pregnancy. The RalFe ANRS160 study was a nonrandomized, open-label, multicenter trial enrolling HIV-infected pregnant women receiving a combined antiretroviral regimen containing 400 mg raltegravir twice daily. Biological samples were collected during the third trimester of pregnancy (between 30 and 37 weeks of gestational age) and at postpartum (4 to 6 weeks after delivery).

Funder

Agence Nationale de Recherches sur le Sida et les Hépatites Virales

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00759-20

Reference41 articles.

1. WHO. 2020. Global guidance on criteria and processes for validation: elimination of Mother-to-Child Transmission of HIV and Syphilis. World Health Organization, Geneva, Switzerland.

2. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006

3. Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention

4. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetic and toxicological considerations affecting antiretroviral drug dosing in pregnant women;Expert Opinion on Drug Metabolism & Toxicology;2024-05-14

2. Long-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman Living With Human Immunodeficiency Virus;Clinical Infectious Diseases;2024-05-03

3. Physiologically Based Pharmacokinetic Modelling of UGT Substrate Drugs Lamotrigine and Raltegravir during Pregnancy;Future Pharmacology;2024-04-10

4. Total, Unbound, Renal, and Hepatic Clearances of Raltegravir and the Formation and Elimination Clearances of Raltegravir Glucuronide in Pregnant Women;The Journal of Clinical Pharmacology;2023-06-20

5. Maintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST study;Journal of Antimicrobial Chemotherapy;2023-05-30